The test is EU approved for use primarily by the professional health care, which is because blood sampling is crucial to the quality of the test result. If you do just the right thing during the sampling (watch the instruction film and follow the instructions carefully in the package leaflet), the test will be reliable, in accordance with the clinical studies that have been performed.
The test measures the antibodies IgM and IgG, which means that if the Coronavirus is present in the body, after three days there are also antibodies. Day 1-3 after a person is infected by the virus, there are no antibodies in the body. Day 4, there is enough for the test to be able to detect it reliably.
Most people infected with Covid-19 begin to show symptoms on day 7-14 after becoming infected. This means that the test can detect if the person is already infected before the person has any symptoms. When the symptoms begin to appear, there are a lot of antibodies throughout the body, which makes the test very reliable. This has been demonstrated in clinical trials and the safety of the test increases the longer the person carries the virus. Therefore, it can be good to test again after 5-10 days, if the test has shown negative at the first sampling, to ensure that the person really does not carry the Coronavirus.
Since antibodies remain in the body after the symptoms disappear and the person recovers, antibodies can still be detected with these tests, so you can see if the person has had Covid-19.
The test is EU-approved to be used mainly by professional healthcare, which is because the sampling in the nose is decisive for the quality of the test results. If you do just the right thing during the sampling (watch the instruction film and follow the instructions carefully in the package leaflet), the test will be reliable, in accordance with the clinical studies that have been performed.
The test measures the antigens that attach to the virus body and is designed for in vitro qualitative detection of SARS-CoV-2 neutrocapsid antigen in nasal (NS) swab samples directly from individuals suspected of being infected with COVID-19, within the first 5 days after the onset of symptoms.
The antigen is generally detectable in samples taken in the upper respiratory tract during the acute phase of infection. A positive test result indicates the presence of viral antigens, but the clinical correlation with the patient’s medical history and other diagnostic information is necessary to determine the infection status.
A negative outcome should be treated as presumptive, which does not exclude a SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. A negative result should be seen in the light of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and if necessary confirmed by a molecular analysis, for patient management.
There are two types of tests available for COVID-19: viral test and antibody test. RT-PCR tests and antigen tests are both viral tests that detect the presence of SARS-CoV-2 from upper nasal samples. The RT-PCR test focuses on the genomic information (RNA) of the virus; however, the COVID-19 antigen test kit detects bits of proteins that make up the SARS-CoV-2 virus. The WHO recommends both RT-PCR tests and antigen tests for the diagnosis of active coronavirus infection.